Sens. Maggie Hassan, D-N.H., and Roger Marshall, R-Kan., introduced the Stop Superbugs Act on Aug. 4 alongside a Joint Economic Committee-Minority report estimating antimicrobial resistance costs the U.S. healthcare system at least $5.7 billion annually.
Here are five things to know:
- The bill would formally authorize the National Institutes of Health’s Antimicrobial Resistance Leadership Group grant to help facilitate clinical trials for new antibiotics.
- The legislation outlines four priorities. The NIH grant would support rapid recruitment of clinical trial participants, community-based recruitment outreach, pairing new antibiotics with better diagnostics during clinical trials and development of patient-reported outcomes.
- Drug-resistant infections remain a major public health burden. According to the report, more than 2.8 million people in the U.S. develop antimicrobial-resistant infections each year and more than 35,000 die. It estimated the infections cost the healthcare system at least $5.7 billion annually.
- The true economic impact is likely higher. The report said the $5.7 billion estimate excludes follow-up healthcare costs, lost productivity, patient out-of-pocket expenses and long-term health effects associated with antimicrobial-resistant infections.
- The report cites market challenges slowing antibiotic development. New antibiotics are expensive to develop, generate limited financial returns and struggle to compete with low-cost generic antibiotics, creating a need for federal action to support innovation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
